Incannex Healthcare reports quarterly adjusted loss of A$11.23 per share
Revenue was zero and the quarterly loss was A$5.59 million. The lone analyst forecast had been for a 75-cent-per-share loss.
98 a year earlier. The lone analyst estimate was for a loss of 75 cents per share. Revenue came in at zero, matching expectations. 59 million.
1% year to date. Analysts' mean earnings estimate was unchanged over the past 30 days, with no estimate revisions in the last 30 days. The average analyst rating is buy, based on 1 strong buy or buy recommendation, no hold and no sell or strong sell. The biotechnology & medical research peer group also has an average buy recommendation.
32. m. UTC shows figures in Australian dollars unless otherwise stated. For the quarter ended Jun.
20, marked Beat. For the quarter ended Mar. 83, marked Missed. For the quarter ended Dec.
83, marked Missed. For the quarter ended Jun. 95, marked Missed.